Therese M. Roth
University of Michigan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Therese M. Roth.
American Journal of Medical Genetics Part A | 2008
Therese M. Roth; Elizabeth M. Petty; Kate F. Barald
The Neurofibromatosis Type 1 (NF1) gene functions as a tumor suppressor gene. Loss of its protein, neurofibromin, in the autosomal dominant disorder NF1 is associated with peripheral nervous system tumors, particularly neurofibromas, benign lesions in which the major cell type is the Schwann Cell (SC). Benign and malignant human tumors found in NF1 patients are heterogeneous with respect to their cellular composition. The number and size of neurofibromas in NF1 patients has been shown to increase during pregnancy, with, in some cases, post‐partum regression, which suggests hormonal involvement in this increase. However, in this review, we consider evidence from the literature that both direct hormonal influence on tumor growth and on angiogenesis may contribute to these effects.
Development | 2012
Lisa M. Bank; Lynne M. Bianchi; Fumi Ebisu; Dov Lerman-Sinkoff; Elizabeth Smiley; Yu Chi Shen; Poornapriya Ramamurthy; Deborah L. Thompson; Therese M. Roth; Christine R. Beck; Matthew Flynn; Ryan Teller; Luming Feng; G. Nicholas Llewellyn; Brandon B. Holmes; Cyrrene Sharples; Jaeda Coutinho-Budd; Stephanie A. Linn; Andrew P. Chervenak; David F. Dolan; Jennifer Benson; Ariane Kanicki; Catherine A. Martin; Richard A. Altschuler; Alicia E. Koch; Ethan M. Jewett; John A. Germiller; Kate F. Barald
This study is the first to demonstrate that macrophage migration inhibitory factor (MIF), an immune system ‘inflammatory’ cytokine that is released by the developing otocyst, plays a role in regulating early innervation of the mouse and chick inner ear. We demonstrate that MIF is a major bioactive component of the previously uncharacterized otocyst-derived factor, which directs initial neurite outgrowth from the statoacoustic ganglion (SAG) to the developing inner ear. Recombinant MIF acts as a neurotrophin in promoting both SAG directional neurite outgrowth and neuronal survival and is expressed in both the developing and mature inner ear of chick and mouse. A MIF receptor, CD74, is found on both embryonic SAG neurons and adult mouse spiral ganglion neurons. Mif knockout mice are hearing impaired and demonstrate altered innervation to the organ of Corti, as well as fewer sensory hair cells. Furthermore, mouse embryonic stem cells become neuron-like when exposed to picomolar levels of MIF, suggesting the general importance of this cytokine in neural development.
Jaro-journal of The Association for Research in Otolaryngology | 2006
Lynne M. Bianchi; Zeeba Daruwalla; Therese M. Roth; Naweah P. Attia; Nicholas W. Lukacs; Ayo Lynn Richards; Ian O. White; Susan J. Allen; Kate F. Barald
The target-derived factors necessary for promoting initial outgrowth from the statoacoustic ganglion (SAG) to the inner ear have not been fully characterized. In the present study, conditioned medium from embryonic Immortomouse inner ear cell lines that maintain many characteristics of developing inner ear sensory epithelia were screened for neurite-promoting activity. Conditioned medium found to be positive for promoting SAG neurite outgrowth and neuronal survival was then tested for the presence of chemokines, molecules that have not previously been investigated for promoting SAG outgrowth. One candidate molecule, monocyte chemotactic protein 1 (MCP-1), was detected in the conditioned medium and subsequently localized to mouse hair cells by immunocytochemistry. In vitro studies demonstrated that function-blocking MCP-1 antibodies decreased the amount of SAG neurite outgrowth induced by the conditioned medium and that subsequent addition of MCP-1 protein was able to promote outgrowth when added to the antibody-treated conditioned medium. The use of the Immortomouse cell lines proved valuable in identifying this candidate cofactor that promotes outgrowth of early-stage SAG nerve fibers and is expressed in embryonic hair cells.
Developmental Dynamics | 2008
Therese M. Roth; Poornapriya Ramamurthy; David Muir; Margaret R. Wallace; Yuan Zhu; Lou Chang; Kate F. Barald
Loss of neurofibromin, the protein product of the tumor suppressor gene neurofibromatosis type 1 (NF1), is associated with neurofibromas, composed largely of Schwann cells. The number and size of neurofibromas in NF1 patients have been shown to increase during pregnancy. A mouse embryonic stem cell (mESC) model was used, in which mESCs with varying levels of neurofibromin were differentiated into Schwann‐like cells. NF1 cell lines derived from a malignant and a benign human tumor were used to study proliferation in response to hormones. Estrogen and androgen receptors were not expressed or expressed at very low levels in the NF1+/+ cells, at low levels in NF1+/−cells, and robust levels in NF1−/−cells. A 17β‐estradiol (E2) metabolite, 2‐methoxy estradiol (2ME2) is cytotoxic to the NF1−/− malignant tumor cell line, and inhibits proliferation in the other cell lines. 2ME2 or its derivatives could provide new treatment avenues for NF1 hormone‐sensitive tumors at times of greatet hormonal influence. Developmental Dynamics 237:513–524, 2008.
Glia | 2007
Therese M. Roth; Poornapriya Ramamurthy; Fumi Ebisu; Robert P. Lisak; Beverly Bealmear; Kate F. Barald
The neurofibromatosis Type 1 (NF1) gene functions as a tumor suppressor gene. One known function of neurofibromin, the NF1 protein product, is to accelerate the slow intrinsic GTPase activity of Ras to increase the production of inactive rasGDP, with wide‐ranging effects on p21ras pathways. Loss of neurofibromin in the autosomal dominant disorder NF1 is associated with tumors of the peripheral nervous system, particularly neurofibromas, benign lesions in which the major affected cell type is the Schwann cell (SC). NF1 is the most common cancer predisposition syndrome affecting the nervous system. We have developed an in vitro system for differentiating mouse embryonic stem cells (mESC) that are NF1 wild type (+/+), heterozygous (+/−), or null (−/−) into SC‐like cells to study the role of NF1 in SC development and tumor formation. These mES‐generated SC‐like cells, regardless of their NF1 status, express SC markers correlated with their stage of maturation, including myelin proteins. They also support and preferentially direct neurite outgrowth from primary neurons. NF1 null and heterozygous SC‐like cells proliferate at an accelerated rate compared to NF1 wild type; this growth advantage can be reverted to wild type levels using an inhibitor of MAP kinase kinase (Mek). The mESC of all NF1 types can also be differentiated into neuron‐like cells. This novel model system provides an ideal paradigm for studies of the role of NF1 in cell growth and differentiation of the different cell types affected by NF1 in cells with differing levels of neurofibromin that are neither transformed nor malignant.
Molecular Biology of the Cell | 2012
Therese M. Roth; C.-Y. Ason Chiang; Mayu Inaba; Hebao Yuan; Viktoria Salzmann; Caitlin E. Roth; Yukiko M. Yamashita
A novel mechanism is found by which Drosophila male germline stem cells (GSCs) slow their cell cycle under limited nutrient conditions. Upon culturing in poor media, GSCs misorient their centrosomes with respect to the stem cell niche, activating the centrosome orientation checkpoint and leading to slowdown of the cell cycle.
British Journal of Cancer | 2015
Yu Chi Shen; Ravi Upadhyayula; Stephanie Cevallos; Ryan J. Messick; Tammy Hsia; Mathew P. Leese; Douglas M. Jewett; Daysha Ferrer-Torres; Therese M. Roth; Wolfgang Dohle; Barry V. L. Potter; Kate F. Barald
Background:Both the number and size of tumours in NF1 patients increase in response to the rise in steroid hormones seen at puberty and during pregnancy. The size of tumours decreases after delivery, suggesting that hormone-targeting therapy might provide a viable new NF1 treatment approach. Our earlier studies demonstrated that human NF1 tumour cell lines either went through apoptosis or ceased growth in the presence of 2-methoxyoestradiol (2ME2), a naturally occurring anticancer metabolite of 17-β estradiol. Previous reports of treatment with sulfamoylated steroidal and non-steroidal derivatives of 2ME2 showed promising reductions in tumour burden in hormone-responsive cancers other than NF1. Here we present the first studies indicating that 2ME2 derivatives could also provide an avenue for treating NF1, for which few treatment options are available.Methods:STX3451, (2-(3-Bromo-4,5-dimethoxybenzyl)-7-methoxy-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline), a non-steroidal sulphamate analogue of 2ME2, was tested in dose-dependent studies of malignant and benign NF1 human tumour cell lines and cell lines with variable controlled neurofibromin expression. The mechanisms of action of STX3451 were also analysed.Results:We found that STX3451-induced apoptosis in human malignant peripheral nerve sheath tumour (MPNST) cell lines, even in the presence of elevated oestrogen and progesterone. It inhibits both PI3 kinase and mTOR signalling pathways. It disrupts actin- and microtubule-based cytoskeletal structures in cell lines derived from human MPNSTs and in cells derived from benign plexiform neurofibromas. STX3451 selectively kills MPNST-derived cells, but also halts growth of other tumour-derived NF1 cell lines.Conclusion:STX3451 provides a new approach for inducing cell death and lowering tumour burden in NF1 and other hormone-responsive cancers with limited treatment options.
Archive | 2012
Therese M. Roth; Yukiko M. Yamashita; Jun Cheng
Stem cells are well known for their self-renewal ability and differentiation potential. It is critical to regulate stem cell self-renewal and differentiation, both during fast growth in development and tissue homeostasis in adulthood. One way to maintain tissue homeostasis is through asymmetric stem cell division, in which centrosomes play an important role in establishing mitotic spindles by acting as a microtubule organization center (MTOC). In this chapter, the asymmetric behavior of centrosomes during stem cell division will be discussed based on their structural, behavioral, and developmental asymmetry.
Developmental Biology | 2006
Therese M. Roth; Poornapriya Ramamurthy; Fumi Ebisu; Kate F. Barald
Archive | 2008
Therese M. Roth; Elizabeth M. Petty; Kate F. Barald